AJOVista LLC Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

AJOVista LLC purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 4th quarter, Holdings Channel reports. The fund purchased 361 shares of the pharmaceutical company’s stock, valued at approximately $147,000.

A number of other institutional investors have also recently modified their holdings of the business. Arlington Trust Co LLC grew its position in Vertex Pharmaceuticals by 97.1% during the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 33 shares during the period. Fortitude Family Office LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $30,000. Baystate Wealth Management LLC increased its stake in Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 25 shares in the last quarter. OFI Invest Asset Management purchased a new position in Vertex Pharmaceuticals in the 3rd quarter valued at approximately $25,000. Finally, NBC Securities Inc. acquired a new position in Vertex Pharmaceuticals during the third quarter worth $34,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Amit Sachdev sold 3,222 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now directly owns 74,364 shares in the company, valued at approximately $31,250,727.36. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the sale, the executive vice president now owns 55,804 shares of the company’s stock, valued at $23,755,762.80. The disclosure for this sale can be found here. Insiders sold 12,381 shares of company stock valued at $5,203,249 over the last quarter. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Up 0.2 %

NASDAQ:VRTX traded up $0.92 on Friday, hitting $401.08. 1,064,066 shares of the stock were exchanged, compared to its average volume of 1,004,237. The stock has a fifty day moving average of $409.06 and a 200-day moving average of $399.73. The stock has a market cap of $103.66 billion, a PE ratio of 28.88, a PEG ratio of 1.88 and a beta of 0.39. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $320.01 and a fifty-two week high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The firm had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the prior year, the company earned $3.33 EPS. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on VRTX. Maxim Group cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. JPMorgan Chase & Co. upped their price target on shares of Vertex Pharmaceuticals from $390.00 to $438.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Cantor Fitzgerald reissued an “overweight” rating and set a $440.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 20th. Oppenheimer restated an “outperform” rating and set a $500.00 price objective on shares of Vertex Pharmaceuticals in a research report on Monday, April 15th. Finally, Wells Fargo & Company increased their target price on Vertex Pharmaceuticals from $500.00 to $540.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three research analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $430.86.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.